Last reviewed · How we verify
NCT06888973: MSCs in AD
Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
Phase 1, PHASE2 trial testing Mesenchymal Stem Cells in Rheumatoid Arthritis in 200 participants. Enrolling by invitation.
1 February 2025
Quick facts
| Lead sponsor | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 February 2025 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 2 locations across Pakistan |
Drugs / interventions tested
- Mesenchymal Stem Cells — full drug profile →
- Placebo
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Systemic Lupus Erythematosus (SLE) — all drugs for Systemic Lupus Erythematosus (SLE) →
- Systemic Sclerosis — all drugs for Systemic Sclerosis →
- Ankylosing Spondylitis (AS) — all drugs for Ankylosing Spondylitis (AS) →
Sponsor
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Who can join
Adults 18 to 50, any sex, with Rheumatoid Arthritis or Systemic Lupus Erythematosus (SLE). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group). The primary outcome measures will be clinical improvement based on the respective disease specific clinical scores, normalization of T-lymphocyte subsets and \> 50% reduction in disease specific antibody titres. The study will also document the type and frequency of any adverse event or side effects, reported by or seen in any of the trial participants. Patients in treatment group will receive single session of MSC therapy and placebo group will receive 0.9% saline solution. The participants will be followed at 3 and 6 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06888973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mesenchymal Stem Cells
Trials testing the same drug.
- NCT06764329 — The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. · Phase 1, PHASE2 · enrolling by invitation
- NCT06205342 — Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain · EARLY_PHASE1 · recruiting
- NCT04519671 — Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease · Phase 1, PHASE2 · terminated
- NCT04506073 — Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Park · Phase 2 · completed
- NCT04519697 — Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease · Phase 1, PHASE2 · terminated
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other National Institute of Blood and Marrow Transplant (NIBMT), Pakistan trials
Trials by the same sponsor.
- NCT06764329 — The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. · Phase 1, PHASE2 · enrolling by invitation
- NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
- NCT06288932 — Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopen · Phase 3 · completed
- NCT07039318 — Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial · Phase 2 · completed
- NCT06490601 — Long Term Beta Thalassemia Treatment: Findings From The Extension Period · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06888973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing